Head-to-head evidence

ALLO-715 vs Trovocabtagene autoleucel (C-CAR088)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

💬 Discuss in AI Terminal →

Multiple Myeloma

Shared mechanism: BCMA · full Multiple Myeloma pipeline

ALLO-715

Developed by Allogene Therapeutics, Inc.

Phase 1 in Multiple Myelomacell therapy (allogeneic anti-BCMA CAR-T)

Weak signal

NCT04093596 · Phase 1 · completed

Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.

Unlock with Research ↗

Trovocabtagene autoleucel (C-CAR088)

Developed by AbelZeta Pharma, Inc.

Phase 1/2 in Multiple MyelomaCAR-T cell therapy

Weak signal

NCT03751293 · Phase 1 · status unknown

This is a very small, open-label, single-arm safety study of a cell therapy with no comparator group and no blinding, and results have not yet been posted.

Unlock with Research ↗

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALLO-715's landscape · Trovocabtagene autoleucel (C-CAR088)'s landscape